Name (Synonyms) | Correlation | |
---|---|---|
drug2329 | Quinquina-Stevia/Azythromycin Wiki | 1.00 |
drug47 | 4Plants/Azythromycin Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D018746 | Systemic Inflammatory Response Syndrome NIH | 0.58 |
D009102 | Multiple Organ Failure NIH | 0.50 |
D058186 | Acute Kidney Injury NIH | 0.23 |
D013577 | Syndrome NIH | 0.10 |
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.09 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.08 |
There is one clinical trial.
Our previous work on plants has indicated significant antimalarial and antiviral activities. Of these plants, two recipes are proposed for evaluation for COVID-19. It is Cinchona, an antimalarial and a combination of 4 plants with antiviral, antimalarial, antitussive and anti-inflammatory properties. The phase II clinical trial, with three arms and at a rate of 77 patients per arm, received the approval of the National Committee for Ethics and Health Research. This is a non-inferiority test aimed at comparing the therapeutic impact in "add on" to Azithromycin, phytomedicines versus Hydroxychloroquine in asymptomatic COVID-19 patients. After 10 days of treatment, viral clearance and symptom progression will be assessed on days 3, 6 and 14. Clinical, paraclinical and laboratory tests will be performed throughout the 3-month trial. Ethical and deontological considerations will be applied
Description: Virologic clearance from admission to discharge at days 3, 6 and 14
Measure: Virologic clearance of throat swabs or lower respiratory tract secretions Time: day 3 to day 14Description: number of patients who developed fever, cough, and any other clinical sign typical of the disease
Measure: COVID-19 symptoms development Time: day 1 to day 14Description: number of participants who developed treatment-related adverse effects
Measure: Adverse effects Time: day 1 to day 14Description: number of patients whose condition worsened on D14
Measure: Worsened condition Time: day 1 to day 14